Xeno Diagnostics Receives 4th Laboratory Excellence Award

Share Article

Xeno has won its 4th consecutive Laboratory Excellence Award following its most recent regulatory inspection.

Xeno Diagnostics has received an award for Laboratory Excellence following its most recent COLA inspection, making this the fourth consecutive inspection for Xeno to receive this award. Xeno has met all criteria for Laboratory Accreditation by COLA, a national healthcare accreditation organization. Accreditation is earned only by laboratories that apply rigid standards of quality in day-to-day operations, demonstrate continued accuracy in the performance of proficiency testing, and pass a rigorous on-site laboratory survey with no citations.

While the Laboratory Excellence award reflects Xeno’s capabilities in clinical laboratory testing, Xeno’s President, Dan Follas, explains how this award also reflects the high quality of their research services, “With any laboratory service, attention to detail is critical. At Xeno we put the same attention into our research studies as we do in our routine clinical work.” This award demonstrates Xeno’s unwavering commitment to providing accurate and reliable test results for its clients. Xeno doubled the size of its Northside facility in 2016, and added staff members to support its growing operation. Xeno’s firm grounding in clinical testing and continued success as a contract research organization make them a great addition to Indiana’s growing biotechnology industry.

About Xeno Diagnostics:
Xeno Diagnostics was founded in 2007, with a focus on providing new products and services for researchers studying porcine models of disease and inflammation. This included the development of antibodies, test procedures, and functional cell-based assays. Client demand shifted this testing focus into other animal species. Xeno quickly adapted, and now offers assays for many species, including non-human primates (baboon, cynomolgus macaque, and rhesus macaque) bovine, and human. At present, Xeno provides contract research services to pharmaceutical and biotech companies in the preclinical and phase I stages of drug development. Therapeutic areas include immuno-oncology, transplantation, biomaterials, and inflammation. To learn more about Xeno Diagnostics and their contract research services, visit http://www.xenodiagnostics.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jon Follas
Visit website